Acquisition · Healthcare & Life Sciences

Zenex buys SAVAVET pet care business

By Startup Enthusiast · 30 September 2026

What they do

Zenex makes veterinary medicines for livestock, poultry and pets, and is backed by private equity investor Multiples

It has bought SAVAVET, the companion animal unit of SAVA Healthcare, on an undisclosed price

SAVAVET sells about 70 brands through 165 stockists and more than 6,000 vets, making this Zenex's third buyout under Multiples

Pet healthcare is one of the fastest-growing parts of India's animal health market.
The deal gives Zenex established brands and vet ties.
SAVA Healthcare can focus on human health.

Zenex makes and sells animal medicines and feed supplements for livestock, poultry and pets.
Its range covers antibiotics, vitamin injections, hormones, udder-infection treatments, poultry vaccines and growth promoters.
It makes products at its Haridwar plant and sells to farmers and vets through a field team of 1,200+ sales staff.
It earns by selling these products in India and in 15+ export countries across the Middle East, Africa, Eastern Europe and Southeast Asia.
Revenue was about ₹1,023 crore in FY 2025, up 24% on the year before.
In 2026 it bought a majority of a Dutch animal nutrition firm, widening its reach abroad.

Multiples Alternate Asset Management (private equity investor) — Invested in Zenex before its recent buyouts.

Dr. Arun Atrey leads Zenex as managing director and chief executive (as named in 2023 and early 2026 coverage); Aniruddha Rajurkar became CEO in April 2026 after leading SAVA Healthcare and Shield Healthcare.